Bionano Genomics, Inc. BNGO
We are a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. Our mission is to transform the way the world sees the genome through optical genome mapping ("OGM") solutions, nucleic acid extraction and purification systems, diagnostic services and software. We offer OGM solutions for applications across basic, translational and clinical research, and for other applications including bioprocessing. We offer a platform-agnostic software solution, which integrates next-generation sequencing ("NGS"), microarray and OGM data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view. The Company also offers nucleic acid extraction and purification solutions using proprietary isotachophoresis ("ITP") technology. Through our Bionano Laboratories business, we also provide OGM-based diagnostic testing services.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $28.5M | $30.8M | $36.1M | $27.8M | $18.0M | $8.5M | $10.1M | $12.0M | $9.5M | — |
| Cost of revenue | $15.3M | $30.4M | $26.6M | $21.9M | $14.1M | $5.7M | $6.8M | $8.7M | $6.0M | — |
| Gross profit | $13.2M | $380.0K | $9.6M | $5.9M | $3.9M | $2.8M | $3.4M | $3.3M | $3.5M | — |
| R&D | $11.4M | $24.8M | $54.0M | $49.0M | $22.5M | $10.3M | $9.1M | $9.5M | $12.0M | — |
| SG&A | $35.1M | $51.9M | $92.8M | $88.6M | $58.5M | $31.1M | $20.2M | $14.2M | $14.1M | — |
| Total operating expenses | $46.5M | $104.4M | $224.8M | $137.6M | $81.0M | $41.3M | $29.2M | $23.7M | $26.7M | — |
| Operating income | -$33.3M | -$104.0M | -$215.2M | -$131.7M | -$77.1M | -$38.6M | -$25.9M | -$20.4M | -$23.2M | — |
| Interest expense | — | — | $5.1M | $298.0K | $927.0K | $2.5M | $2.3M | $1.4M | $590.9K | — |
| Pre-tax income | -$26.3M | -$112.0M | -$232.4M | -$130.7M | -$78.2M | -$41.1M | -$29.8M | -$18.5M | -$23.3M | — |
| Income tax | $67.0K | $33.0K | $62.0K | $1.9M | $5.7M | $29.0K | $21.0K | $15.5K | $18.6K | — |
| Net income | -$26.4M | -$112.0M | -$232.5M | -$132.6M | -$72.4M | -$41.1M | -$29.8M | -$18.5M | -$23.4M | — |
| EPS, basic | -4.85 | -88.13 | -408.60 | -4.58 | -0.26 | — | — | — | — | — |
| EPS, diluted | -4.85 | -88.13 | -408.60 | -4.58 | -0.26 | -0.39 | -1.99 | -2.61 | -8.65 | — |
| Shares, diluted (wtd. avg.) | $5.4M | $1.3M | $569.0K | $28.9M | $276.8M | — | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $3.0M | $9.2M | $17.9M | $5.1M | $24.6M | $38.4M | $17.3M | $16.5M | $1.0M | — |
| Short-term investments | $16.3M | $302.0K | $48.8M | $108.1M | $226.0M | $0 | — | — | — | — |
| Receivables | $5.2M | $4.8M | $9.3M | $7.0M | $4.9M | $2.8M | $6.3M | $4.5M | $3.4M | — |
| Inventory | $7.8M | $13.3M | $27.6M | $29.8M | $12.4M | $3.3M | $3.4M | $1.1M | $1.7M | — |
| Total current assets | $45.4M | $39.5M | $140.1M | $157.3M | $272.4M | $46.8M | $28.3M | $23.0M | $7.1M | — |
| Property, plant and equipment | $14.8M | $19.2M | $23.3M | $18.0M | $10.3M | $4.9M | $1.9M | $1.8M | $3.0M | — |
| Goodwill | — | — | $0 | $77.3M | $56.2M | $7.2M | $0 | — | — | — |
| Other intangibles | $4.3M | $9.7M | $34.0M | $41.1M | $26.8M | $1.5M | $0 | — | — | — |
| Total assets | $73.6M | $76.7M | $214.4M | $307.5M | $377.1M | $60.5M | $30.2M | $24.8M | $10.1M | — |
| Accounts payable | $5.6M | $7.0M | $10.4M | $12.5M | $10.8M | $2.9M | $2.7M | $1.4M | $2.3M | — |
| Short-term debt | — | — | — | — | — | $0 | $20.1M | $0 | $6.7M | — |
| Total current liabilities | $22.9M | $37.3M | $100.0M | $35.9M | $21.8M | $8.9M | $26.4M | $4.5M | $16.7M | — |
| Long-term debt | — | — | — | — | $0 | $16.3M | $0 | $9.0M | $0 | — |
| Total liabilities | $29.2M | $41.3M | $118.2M | $58.1M | $40.0M | $25.4M | $26.6M | $14.7M | $17.4M | — |
| Retained earnings | -$719.6M | -$693.2M | -$581.2M | -$348.7M | -$216.1M | -$143.7M | -$102.6M | -$72.8M | -$54.3M | — |
| Total equity | $44.4M | $35.4M | $96.2M | $249.4M | $337.1M | $35.1M | $3.6M | $10.1M | -$50.2M | -$27.3M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$16.3M | -$68.9M | -$125.2M | -$124.8M | -$71.9M | -$38.3M | -$29.5M | -$19.9M | -$20.8M | — |
| Depreciation and amortisation | $9.5M | $14.0M | $13.7M | $9.6M | $3.4M | $1.5M | $1.1M | $1.3M | $1.5M | — |
| Stock-based compensation | $4.5M | $9.7M | $15.2M | $22.4M | $9.7M | $1.6M | $1.3M | $1.2M | $382.8K | — |
| Capital expenditure | — | — | — | — | — | $0 | $61.1K | $331.7K | $1.0M | — |
| Investing cash flow | -$12.7M | $73.8M | $24.2M | $82.8M | -$278.1M | -$2.5M | -$61.1K | -$331.7K | -$1.0M | — |
| Financing cash flow | $24.0M | -$13.7M | $113.8M | $23.0M | $336.1M | $61.9M | $30.4M | $35.8M | $17.6M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001411690-26-000007.
Others in SIC 3826
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| A | AGILENT TECHNOLOGIES, INC. | $42.53B | 33.0x | 6.7% |
| WAT | WATERS CORP /DE/ | $40.22B | 38.0x | 7.0% |
| ILMN | ILLUMINA, INC. | $32.95B | 40.0x | -0.7% |
| MTD | METTLER TOLEDO INTERNATIONAL INC/ | $26.95B | 32.0x | 4.0% |
| RVTY | REVVITY, INC. | $14.53B | 62.9x | 3.7% |
| BIO | BIO-RAD LABORATORIES, INC. | $10.33B | 13.9x | 0.7% |
| AVTR | Avantor, Inc. | $10.22B | — | -3.4% |
| BRKR | BRUKER CORP | $8.88B | — | 2.1% |